Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced that Glenn Sammis, a professor and scientific advisor to subsidiary Delic Labs, has received a full professorship at the University of British Columbia in the chemistry department. The announcement also noted that Sammis will be working closely with Dr. Markus Roggen in developing intellectual property (“IP”) for Delic Labs’ cannabis and psilocybin research; he will take a yearlong sabbatical from his position at the university to pursue this research. A federally authorized psilocybin and cannabis research laboratory, Delic Labs is focused on extraction, analytical testing and chemical process development. The facility conducts research and develops product lines for distribution through Delic Corp.’s existing network throughout the United States, including licensed psychedelic wellness clinics. In the announcement, Sammis noted that he looks forward to working with Roggen, calling it a “great honor.” He also noted that the company’s unique and early testing would give the company a first-mover advantage in the medical psychedelic space. Delic Labs was founded by Roggen and Sammis. According to the announcement, DELIC Labs is a leading cannabis analytical and research company with a client list that includes some of the best-known brands around the world. The lab is in the process of applying for a dealer’s license and anticipates commercializing its research and IP moving forward.
To view the full press release, visit https://ibn.fm/m9tG1
About Delic Corp Inc.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.